Antimicrobial

VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a…

4 months ago

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue streamLEXINGTON, Mass., Dec.…

4 months ago

Avails Medical announces the commencement of U.S. Pilot Trial for the eAST™ system

MENLO PARK, Calif., Dec. 3, 2024 /PRNewswire/ -- Avails Medical, Inc., a leader in rapid, automated, and fully electrical antibiotic susceptibility…

4 months ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

- STAR-1 topline results expected in March 2025 -- Over 30 million acne patients seek treatment in the U.S. each…

4 months ago

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026,…

4 months ago

Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel

BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare GlobalWINNIPEG, Manitoba, Nov. 27, 2024…

5 months ago

Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives

SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic…

5 months ago

Teva Takes on Antimicrobial Resistance (AMR): What You Need to Know

NORTHAMPTON, MA / ACCESSWIRE / November 20, 2024 / Antimicrobial resistance (AMR) happens when bacteria no longer respond to antibiotics,…

5 months ago

BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

Additions of ProgenaMatrix® and revyve™ Antimicrobial Wound Gel part of planned expansion of BioStem’s commercial product portfolioPOMPANO BEACH, Fla., Nov.…

5 months ago